Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury.
Hyaluronan (HA), an ionic polymer, is normally present in the alveolar subphase and is known to decrease lung surfactant inactivation caused by serum in vitro. In this study, we examined whether HA can ameliorate the inactivating effects of meconium in vitro and in vivo. Surface activities of various mixtures of Survanta, HA, and meconium were measured using a modified pulsating bubble surfactometer. With meconium, almost all surface activity measures were improved by the addition of HA of several molecular weights at a concentration of 0.25%. Anesthetized, paralyzed rats were maintained on positive-pressure ventilation. After lung injury by instillation of meconium, they were treated with Survanta, Survanta with HA, or control mixtures. Serial measures of blood gases and peak inspiratory pressure were recorded for the duration of the experiment. When the Survanta plus HA group was compared with the Survanta alone group, arterial oxygen tension averaged 117% higher, peak inspiratory pressure was 27% lower at the end of the experiment, and lung compliance also showed significant improvement. These results indicate that HA added to Survanta decreases inactivation caused by meconium in vitro and improves gas exchange and pulmonary mechanics of animals with meconium-induced acute lung injury.
Lu
Karen W
KW
Department of Pediatrics, University of California, San Francisco, San Francisco, California 94110, USA. klu@sfghpeds.ucsf.edu
Goerke
Jon
J
Clements
John A
JA
Taeusch
H William
HW
D000818:Animals; D001158:Arteries / Q000378:metabolism; D001688:Biological Products / Q000494:pharmacology; D004195:Disease Models, Animal; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology*; D066298:In Vitro Techniques; D007231:Infant, Newborn; D007477:Ions; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D055370:Lung Injury; D008297:Male; D008470:Meconium / Q000378:metabolism*; D008471:Meconium Aspiration Syndrome / Q000188:drug therapy*; D010100:Oxygen / Q000378:metabolism; D010743:Phospholipids / Q000737:chemistry; D011108:Polymers / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D013501:Surface-Active Agents / Q000494:pharmacology*; D013997:Time Factors
D001688:Biological Products; D007477:Ions; D010743:Phospholipids; D011108:Polymers; D013501:Surface-Active Agents; D006820:Hyaluronic Acid; C072197:beractant; D010100:Oxygen